Icotrokinra Sustained Ulcerative Colitis Response
The oral drug maintained remission and clinical improvement in study participants through 76 weeks of treatment.
Updated on Oct. 13, 2026 in Cancer
Live Poll
Do you trust that new oral drugs are as effective as traditional intravenous treatments?
Data presented at the ACG meeting showed that the majority of patients with ulcerative colitis sustained clinical response and remission while taking the oral peptide icotrokinra. This research indicates the potential for a new oral option in the early stages of care for those managing the condition.
Why it matters
Ulcerative colitis management often involves long-term reliance on corticosteroids, but this study suggests a possible shift toward targeted oral therapies that help patients remain corticosteroid-free. These findings offer a new potential path for patients seeking sustained disease control.
In an extension of the ANTHEM-UC trial involving 136 participants, the oral IL-23 receptor blocker demonstrated sustained clinical response and endoscopic improvement through 76 weeks of therapy. Most participants maintained remission, though results utilized nonresponder imputation without formal statistical testing.
The players
United States Food and Drug Administration
The federal agency responsible for regulating pharmaceuticals and ensuring the safety and efficacy of medical treatments.
American College of Gastroenterology
A professional medical organization that promotes the study and clinical practice of gastrointestinal health.
The details
Icotrokinra functions as an oral peptide that targets and binds the interleukin-23 (IL-23) receptor to modulate inflammatory pathways associated with ulcerative colitis. In this trial, participants who did not reach adequate response by week 16 were transitioned to a 400 mg dosage to optimize therapeutic outcomes. The study monitored safety and retention across three dosage groups—100 mg, 200 mg, and 400 mg—to evaluate the drug's role in the long-term management of inflammatory bowel disease.
Timeline
March 2026: The FDA approved icotrokinra for the treatment of plaque psoriasis.
October 9-14, 2026: Results were presented at the American College of Gastroenterology (ACG) meeting in Nashville.
Week 76: Researchers evaluated clinical response, remission, and endoscopic improvement.
Week 78: Investigators recorded the final safety visit and treatment retention data.
Health Landscape
The clinical progression of icotrokinra follows the broader trend of developing targeted oral peptides to replace or augment traditional biologic therapies in inflammatory bowel disease. This research extends the findings of the ANTHEM-UC trial, reflecting a shift toward earlier, more precise intervention.
If you are managing ulcerative colitis, these results highlight the potential for oral, non-steroid treatment options that may sustain long-term remission. Talk to your gastroenterologist about current research and whether your treatment plan aligns with emerging therapies that prioritize corticosteroid-free outcomes.
The takeaway
This trial shows that targeted oral peptides can help maintain remission in ulcerative colitis patients for over a year. Patients should keep an eye on emerging treatment guidelines and discuss the benefits of steroid-free maintenance strategies with their care team.
Further reading
For more background on managing chronic bowel conditions, visit the Cancer section.
More information
Review the detailed findings in the J&J clinical study press release.
Live Poll
Do you trust that new oral drugs are as effective as traditional intravenous treatments?
